Under construction – not a live service
Sign in
Enrolling by invitationNo phase

PSMA PET/CT Scan Studied in Non-Prostate Cancers

Studies a PSMA imaging scan in adults with cancers other than prostate cancer.

Key facts

Who runs it
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Where
Bologna, ItalySee the site
Trial code
Registry title
Diagnostic Performance of PET/CT-PSMA in Patients With Non-prostatic PSMA-expressing Neoplasms
Status
Enrolling by invitation
People taking part
1,000 people, planned
Started
17 Sept 2021
Expected to end
Jun 2031
Type of study
Observational
Treatments tested
  • 68Ga-PSMA-11
Record updated
19 February 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a cancer other than prostate cancer. They are sent for a PSMA PET/CT scan as part of their normal care.

Age
18 years or older
Sex
All sexes can join
Disease stage
A cancer other than prostate cancer, sent for a PSMA PET/CT scan for staging, restaging, or before and after treatment

Main reasons for not taking part

  • Pregnancy

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Patients diagnosed with a neoplasm other than prostate carcinoma who are referred to our unit as part of the standard care pathway to undergo a PSMA PET/CT scan for staging, restaging, and pre- and post-treatment evaluation
  • Signed informed consent for the collection and processing of data
  • Minimum age 18 years old."

Who cannot take part

  • pregnancy

Where in Italy

  • Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di BolognaBologna, ItalyNo longer taking part

About the trial

What the trial wants to find out

Study to collect data from PET/CT-PSMA performed in patients with neoplasms expressing PSMA, other than prostate cancer.

Read full original descriptionShow less

Objectives The primary objective is to evaluate the diagnostic performance of PET/CT-PSMA in the staging and management of patients with non-prostatic neoplasms expressing PSMA.

The secondary objective is to analyze the prognostic value of PET-PSMA in such neoplasms and the possible use in the selection of patients eligible for target therapies against neovascularization (i.e. monoclonal anti-VEGF antibodies) and radiopharmaceutical treatments (i.e. 177Lu-PSMA).

The group in the trial

  • MORE PSMA POPULATION

    Patients with tumors other than prostate cancer who may express PSMA

    Treatment: 68Ga-PSMA-11

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Diagnostic Performance of PET/CT-PSMA in Patients With Non-prostatic PSMA-expressing Neoplasms: A Monocentric Observational Experience
Plain-language title
PSMA PET/CT Scan Studied in Non-Prostate CancersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
19 February 2025